MMED (Minimed Group) ROE % Adjusted to Book Value: 0.00% (As of Jan. 2026)


MMED Minimed Group Inc MMED
15 GF Score
Price $14.28
! 1 Warning Sign
View Full Analysis

What is Minimed Group ROE % Adjusted to Book Value?

Minimed Group MMED +0.14% 15 ROE % Adjusted to Book Value is 0.00% as of Jan. 2026. GuruFocus rates MMED with a GF Score™ of 15/100. The stock has 1 warning sign investors should review.

Minimed Group's ROE % for the quarter that ended in Jan. 2026 was -13.21%. Minimed Group's PB Ratio for the quarter that ended in Jan. 2026 was N/A. Minimed Group's ROE % Adjusted to Book Value for the quarter that ended in Jan. 2026 was N/A.

Minimed Group ROE % Adjusted to Book Value Related Terms

Minimed Group ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Minimed Group's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minimed Group ROE % Adjusted to Book Value Chart

Minimed Group Annual Data
Trend Apr23 Apr24 Apr25
ROE % Adjusted to Book Value
0.00 0.00 0.00

Minimed Group Quarterly Data
Apr24 Jan25 Apr25 Oct25 Jan26
ROE % Adjusted to Book Value 0.00 0.00 0.00 0.00 0.00

MMED vs ICUI, WRBY, MMSI: ROE % Adjusted to Book Value Comparison

For the Medical Instruments & Supplies subindustry, Minimed Group's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Minimed Group ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Minimed Group's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Minimed Group's ROE % Adjusted to Book Value falls into.


MMED
15GF Score
Minimed Group Inc MMED
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minimed Group ROE % Adjusted to Book Value Calculation

Minimed Group's ROE % Adjusted to Book Value for the fiscal year that ended in Apr. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-7.38% / N/A
=N/A

Minimed Group's ROE % Adjusted to Book Value for the quarter that ended in Jan. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-13.21% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Minimed Group (MMED) has a ROE % Adjusted to Book Value of 0.00% as of Jan. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Minimed Group and its competitors.
Is Minimed Group's ROE % Adjusted to Book Value too high?
Minimed Group's current ROE % Adjusted to Book Value is 0.00%. Overall, Minimed Group has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Minimed Group's ROE % Adjusted to Book Value compare to ICUI and WRBY?
Minimed Group's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Minimed Group and its competitors. Minimed Group's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minimed Group stock overvalued right now?
Minimed Group (MMED) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Minimed Group's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Minimed Group (MMED), the current ROE % Adjusted to Book Value is 0.00% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minimed Group Business Description

Other Exchanges B8S:Germany
Address 18000 Devonshire Street, Northridge, CA, USA, 91325
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.
15GF Score

Get the complete analysis for MMED

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.28
Price